Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with acromegaly (a condition where the body produces too much growth hormone) that was not brought under control after 6 months of treatment with a type of medication called first-generation somatostatin receptor ligands (fg-SRLs), and you have since been switched to one of two alternative treatments — either a medication called Pasireotide LAR (for at least one week) or a medication called Pegvisomant — as decided by your doctor following standard medical guidelines
- You are willing and able to sign a consent form agreeing to take part in the study (or, where applicable, a substitute consent arrangement can be made)
Who may not be able to join:
- You are under 18 years of age
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sabrina Chiloiro, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phone: +393468788523
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison between Pasireotide LAR and Pegvisomant
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.